Beijing Wantai Biological Pharmacy Enterprise Co Ltd (SHG:603392) — Market Cap & Net Worth
Market Cap & Net Worth: Beijing Wantai Biological Pharmacy Enterprise Co Ltd (603392)
Beijing Wantai Biological Pharmacy Enterprise Co Ltd (SHG:603392) has a market capitalization of $5.66 Billion (CN¥38.69 Billion) as of August 1, 2026. Listed on the SHG stock exchange, this China-based company holds position #3259 globally and #421 in its home market, demonstrating a 4.65% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Beijing Wantai Biological Pharmacy Enterprise Co Ltd's stock price CN¥30.60 by its total outstanding shares 1264392804 (1.26 Billion). See 603392 capital reinvestment ratio to understand how much of operating cash flow is reinvested back into capital assets.
Beijing Wantai Biological Pharmacy Enterprise Co Ltd Market Cap History: 2020 to 2026
Beijing Wantai Biological Pharmacy Enterprise Co Ltd's market capitalization history from 2020 to 2026. Data shows growth from $12.90 Billion to $5.66 Billion (36.54% CAGR).
Beijing Wantai Biological Pharmacy Enterprise Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Beijing Wantai Biological Pharmacy Enterprise Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4.57x
Beijing Wantai Biological Pharmacy Enterprise Co Ltd's market cap is 4.57 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $12.90 Billion | $2.35 Billion | $677.00 Million | 5.48x | 19.05x |
| 2021 | $19.87 Billion | $5.75 Billion | $2.02 Billion | 3.45x | 9.83x |
| 2022 | $16.50 Billion | $11.19 Billion | $4.74 Billion | 1.47x | 3.48x |
| 2023 | $13.90 Billion | $5.51 Billion | $1.25 Billion | 2.52x | 11.14x |
| 2024 | $13.04 Billion | $2.25 Billion | $106.24 Million | 5.81x | 122.71x |
| 2025 | $8.31 Billion | $1.82 Billion | -$398.27 Million | 4.57x | N/A |
Competitor Companies of 603392 by Market Capitalization
Companies near Beijing Wantai Biological Pharmacy Enterprise Co Ltd in the global market cap rankings as of August 1, 2026.
Key companies related to Beijing Wantai Biological Pharmacy Enterprise Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Beijing Wantai Biological Pharmacy Enterprise Co Ltd Historical Marketcap From 2020 to 2026
Between 2020 and today, Beijing Wantai Biological Pharmacy Enterprise Co Ltd's market cap moved from $12.90 Billion to $ 5.66 Billion, with a yearly change of 36.54%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥5.66 Billion | -31.91% |
| 2025 | CN¥8.31 Billion | -36.22% |
| 2024 | CN¥13.04 Billion | -6.22% |
| 2023 | CN¥13.90 Billion | -15.73% |
| 2022 | CN¥16.50 Billion | -16.96% |
| 2021 | CN¥19.87 Billion | +54.04% |
| 2020 | CN¥12.90 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 1st, 2026 the market cap of Beijing Wantai Biological Pharmacy Enterprise Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.66 Billion USD |
| MoneyControl | $5.66 Billion USD |
| MarketWatch | $5.66 Billion USD |
| marketcap.company | $5.66 Billion USD |
| Reuters | $5.66 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. research, develops, produces, and sells biological diagnostic tests and vaccines in China and internationally. The company offers in vitro diagnostics and automated laboratory instruments, including Wan600, Wan BC2800, WanTLA immunoassay and biochemistry analyzers; chemiluminescence and biochemistry tests, including novel diagnostic tests fo… Read more